Dipeptidyl-Peptidase IV (DPP IV/CD26)-Activated Prodrugs: A Successful Strategy for Improving Water Solubility and Oral Bioavailability

Publisher： Bentham Science Publishers

E-ISSN： 1875-533x|22|8|1041-1054

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.22, Iss.8, 2015-03, pp. : 1041-1054

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Azetidine-Based Inhibitors of Dipeptidyl Peptidase IV (DPP IV)

By  

Current Topics in Medicinal Chemistry, Vol. 7, Iss. 6, 2007-03 ,pp. : 597-608

Bentham Science Publishers

Access to resources Recommend Favorite

The Therapeutic Potential of Inhibitors of Dipeptidyl Peptidase IV (DPP IV) and Related Proline-Specific Dipeptidyl Aminopeptidases

By  

Current Medicinal Chemistry, Vol. 12, Iss. 8, 2005-04 ,pp. : 971-998

Bentham Science Publishers

Access to resources Recommend Favorite

CD26/Dipeptidyl Peptidase IV as a Novel Therapeutic Target for Cancer and Immune Disorders

By  

Mini Reviews in Medicinal Chemistry, Vol. 7, Iss. 3, 2007-03 ,pp. : 253-273

Bentham Science Publishers

Access to resources Recommend Favorite

CD26 / Dipeptidyl Peptidase IV: A Regulator of Immune Function and a Potential Molecular Target for Therapy

By  

Current Drug Targets - Immune, Endocrine & Metabolic Disorders, Vol. 4, Iss. 1, 2004-03 ,pp. : 11-18

Bentham Science Publishers

Access to resources Recommend Favorite

Dipeptidyl peptidase-IV (DPP-IV) inhibitors enhance the paracrine antilipolytic effects of neuropeptide Y (NPY)

By  

Inpharma, Vol. 1, Iss. 1607, 2007-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite